Tag: HER2-negative breast cancer

A retrospective cohort study of 123 patients suggests the oral fluoropyrimidine S-1 may deliver longer overall survival than capecitabine as ...

A real-world study of 95 patients in Tokyo confirms that pembrolizumab combined with chemotherapy before and after surgery delivers event-free ...

A study of more than 5,000 US patients with HR-positive/HER2-negative metastatic breast cancer found median survival of only 13.5 months ...

The fight against metastatic breast cancer has taken a significant step forward, as researchers in China have completed one of ...

WASHINGTON — A combination of two immunotherapy drugs produced substantially higher rates of tumor eradication when added to chemotherapy before ...

For young women, the years immediately following childbirth may harbor a stealthier form of breast cancer. A new study from ...

In an intense and promising leap forward in the fight against breast cancer, researchers have unveiled groundbreaking findings on the ...

In a groundbreaking study published in BMC Cancer, researchers have delved deep into the molecular landscape of endocrine-resistant breast cancer, ...

Researchers unveil a groundbreaking immune-based genomic signature that promises to revolutionize treatment strategies for hormone receptor-positive, HER2-negative breast cancer by ...

In the rapidly evolving landscape of metastatic breast cancer treatment, understanding patient preferences has emerged as a critical component for ...